JP2016214245A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016214245A5 JP2016214245A5 JP2016129697A JP2016129697A JP2016214245A5 JP 2016214245 A5 JP2016214245 A5 JP 2016214245A5 JP 2016129697 A JP2016129697 A JP 2016129697A JP 2016129697 A JP2016129697 A JP 2016129697A JP 2016214245 A5 JP2016214245 A5 JP 2016214245A5
- Authority
- JP
- Japan
- Prior art keywords
- eno1
- normalized
- level
- breast cancer
- rna transcript
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100038910 Alpha-enolase Human genes 0.000 claims 36
- 101000882335 Homo sapiens Alpha-enolase Proteins 0.000 claims 36
- VLMZMRDOMOGGFA-WDBKCZKBSA-N festuclavine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C)=C3C2=CNC3=C1 VLMZMRDOMOGGFA-WDBKCZKBSA-N 0.000 claims 36
- 238000000034 method Methods 0.000 claims 22
- 206010006187 Breast cancer Diseases 0.000 claims 15
- 208000026310 Breast neoplasm Diseases 0.000 claims 15
- 108091093088 Amplicon Proteins 0.000 claims 13
- 238000004393 prognosis Methods 0.000 claims 9
- 206010027476 Metastases Diseases 0.000 claims 5
- 238000004590 computer program Methods 0.000 claims 5
- 230000009401 metastasis Effects 0.000 claims 5
- 102000015694 estrogen receptors Human genes 0.000 claims 4
- 108010038795 estrogen receptors Proteins 0.000 claims 4
- 239000002299 complementary DNA Substances 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- 101001038034 Homo sapiens Lysophosphatidic acid receptor 6 Proteins 0.000 claims 2
- 102100040406 Lysophosphatidic acid receptor 6 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 1
- 238000010839 reverse transcription Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26376309P | 2009-11-23 | 2009-11-23 | |
| US61/263,763 | 2009-11-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540103A Division JP5964752B2 (ja) | 2009-11-23 | 2010-11-19 | 癌の臨床転帰を予測する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018145578A Division JP7042717B2 (ja) | 2009-11-23 | 2018-08-02 | 癌の臨床転帰を予測する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016214245A JP2016214245A (ja) | 2016-12-22 |
| JP2016214245A5 true JP2016214245A5 (https=) | 2017-03-30 |
Family
ID=44060376
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540103A Active JP5964752B2 (ja) | 2009-11-23 | 2010-11-19 | 癌の臨床転帰を予測する方法 |
| JP2016129697A Pending JP2016214245A (ja) | 2009-11-23 | 2016-06-30 | 癌の臨床転帰を予測する方法 |
| JP2018145578A Active JP7042717B2 (ja) | 2009-11-23 | 2018-08-02 | 癌の臨床転帰を予測する方法 |
| JP2020218527A Pending JP2021058207A (ja) | 2009-11-23 | 2020-12-28 | 癌の臨床転帰を予測する方法 |
| JP2022123265A Pending JP2022166064A (ja) | 2009-11-23 | 2022-08-02 | 癌の臨床転帰を予測する方法 |
| JP2022129605A Pending JP2022169647A (ja) | 2009-11-23 | 2022-08-16 | 癌の臨床転帰を予測する方法 |
| JP2023213416A Active JP7823012B2 (ja) | 2009-11-23 | 2023-12-18 | 癌の臨床転帰を予測する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540103A Active JP5964752B2 (ja) | 2009-11-23 | 2010-11-19 | 癌の臨床転帰を予測する方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018145578A Active JP7042717B2 (ja) | 2009-11-23 | 2018-08-02 | 癌の臨床転帰を予測する方法 |
| JP2020218527A Pending JP2021058207A (ja) | 2009-11-23 | 2020-12-28 | 癌の臨床転帰を予測する方法 |
| JP2022123265A Pending JP2022166064A (ja) | 2009-11-23 | 2022-08-02 | 癌の臨床転帰を予測する方法 |
| JP2022129605A Pending JP2022169647A (ja) | 2009-11-23 | 2022-08-16 | 癌の臨床転帰を予測する方法 |
| JP2023213416A Active JP7823012B2 (ja) | 2009-11-23 | 2023-12-18 | 癌の臨床転帰を予測する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20110123990A1 (https=) |
| EP (4) | EP2504451B1 (https=) |
| JP (7) | JP5964752B2 (https=) |
| AU (1) | AU2010321829B2 (https=) |
| CA (2) | CA3043089A1 (https=) |
| DK (1) | DK2504451T3 (https=) |
| ES (1) | ES2735993T3 (https=) |
| HU (1) | HUE044374T2 (https=) |
| IL (5) | IL219051A (https=) |
| MX (3) | MX337650B (https=) |
| NZ (1) | NZ599194A (https=) |
| PL (1) | PL2504451T3 (https=) |
| WO (1) | WO2011063274A2 (https=) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| ES2636470T3 (es) | 2004-04-09 | 2017-10-05 | Genomic Health, Inc. | Marcadores de expresión génica para predecir la respuesta a la quimioterapia |
| CA2585571C (en) * | 2004-11-05 | 2020-01-21 | Genomic Health, Inc. | Predicting response to chemotherapy using gene expression markers |
| US7888019B2 (en) | 2006-03-31 | 2011-02-15 | Genomic Health, Inc. | Genes involved estrogen metabolism |
| AU2009262022A1 (en) * | 2008-06-26 | 2009-12-30 | Dana-Farber Cancer Institute, Inc. | Signatures and determinants associated with metastasis and methods of use thereof |
| US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
| MX337650B (es) * | 2009-11-23 | 2016-03-14 | Genomic Health Inc | Metodos para predecir el desenlace clinico del cancer. |
| NZ600268A (en) | 2010-01-11 | 2014-08-29 | Genomic Health Inc | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
| GB201009798D0 (en) | 2010-06-11 | 2010-07-21 | Immunovia Ab | Method,array and use thereof |
| EP3812469A1 (en) | 2010-07-07 | 2021-04-28 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| IL243203A (en) | 2010-07-27 | 2017-04-30 | Genomic Health Inc | Method for using gene expression to determine prognosis of prostate cancer |
| US9605319B2 (en) | 2010-08-30 | 2017-03-28 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
| US8916344B2 (en) | 2010-11-15 | 2014-12-23 | Exact Sciences Corporation | Methylation assay |
| US8361720B2 (en) | 2010-11-15 | 2013-01-29 | Exact Sciences Corporation | Real time cleavage assay |
| CA2831074A1 (en) * | 2011-03-26 | 2012-10-04 | Oregon Health And Science University | Gene expression predictors of cancer prognosis |
| US20140154691A1 (en) * | 2011-06-22 | 2014-06-05 | Oncocyte Corporation | Methods and Compositions for the Treatment and Diagnosis of Bladder Cancer |
| US20140302042A1 (en) * | 2011-07-01 | 2014-10-09 | Dana-Farber Cancer Institute, Inc. | Methods of predicting prognosis in cancer |
| EP2732423A4 (en) * | 2011-07-13 | 2014-11-26 | Multiple Myeloma Res Foundation Inc | METHOD FOR DETECTING AND DISTRIBUTING DATA |
| CN104080924A (zh) * | 2011-08-16 | 2014-10-01 | 昂科赛特公司 | 用于治疗和诊断乳腺癌的方法和组合物 |
| SG10202010758SA (en) * | 2011-11-08 | 2020-11-27 | Genomic Health Inc | Method of predicting breast cancer prognosis |
| JP5805518B2 (ja) | 2011-12-21 | 2015-11-04 | 株式会社島津製作所 | マルチプレックス大腸がんマーカーパネル |
| DK3179393T3 (da) | 2012-01-31 | 2020-07-27 | Genomic Health Inc | Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft |
| GB201206323D0 (en) * | 2012-04-10 | 2012-05-23 | Immunovia Ab | Methods and arrays for use in the same |
| US20150184247A1 (en) * | 2012-04-20 | 2015-07-02 | Memorial Sloan-Kettering Cancer Center | Gene expression profiles associated with metastatic breast cancer |
| WO2014055398A1 (en) | 2012-10-05 | 2014-04-10 | Siemens Healthcare Diagnostics Inc. | Method for detecting an increased risk or incidence of colorectal cancer |
| CA2891653A1 (en) | 2012-11-16 | 2014-05-22 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| CA2902916C (en) | 2013-03-14 | 2018-08-28 | Mayo Foundation For Medical Education And Research | Detecting neoplasm |
| KR101672531B1 (ko) * | 2013-04-18 | 2016-11-17 | 주식회사 젠큐릭스 | 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도 |
| MX369911B (es) * | 2013-05-30 | 2019-11-26 | Genomic Health Inc | Método basado en expresión génica para clasificar pacientes con cãncer de riñón de acuerdo al riesgo de recurrencia. |
| US10392667B2 (en) * | 2013-06-07 | 2019-08-27 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients |
| WO2015138769A1 (en) * | 2014-03-12 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for assessing patients with non-small cell lung cancer |
| CA2947624A1 (en) * | 2014-05-13 | 2015-11-19 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| DK3198035T3 (da) | 2014-09-26 | 2023-01-30 | Allarity Therapeutics Europe ApS | Fremgangsmåder til forudsigelse af medicinrespons |
| WO2016092299A1 (en) * | 2014-12-09 | 2016-06-16 | Medical Research Council | Methods and kits for predicting the response to therapy of cancer |
| US10435755B2 (en) | 2015-03-27 | 2019-10-08 | Exact Sciences Development Company, Llc | Detecting esophageal disorders |
| CN114574585A (zh) | 2015-08-31 | 2022-06-03 | 梅约医药教育及研究基金会 | 检测胃肿瘤 |
| CN108350485A (zh) | 2015-10-30 | 2018-07-31 | 精密科学发展有限责任公司 | 血浆dna的多重扩增检测测定以及分离和检测 |
| CA3008273A1 (en) | 2015-12-18 | 2017-06-22 | Clear Gene, Inc. | Methods, compositions, kits and devices for rapid analysis of biological markers |
| CN109563546B (zh) | 2016-05-05 | 2022-09-09 | 精密科学发展有限责任公司 | 通过分析甲基化dna来检测肺肿瘤 |
| SG11201901466PA (en) * | 2016-09-07 | 2019-03-28 | Agency Science Tech & Res | A method of identifying risk of cancer and therapeutic options |
| US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| KR102892245B1 (ko) | 2017-01-27 | 2025-11-27 | 이그젝트 싸이언스 디블롭먼트 컴패니, 엘엘씨 | 메틸화된 dna 분석에 의한 결장 신조직형성의 검출 |
| WO2018212192A1 (ja) * | 2017-05-18 | 2018-11-22 | 京都府公立大学法人 | 癌の予後及び／又は転移可能性を評価する方法及びマーカー |
| US12275994B2 (en) * | 2017-06-22 | 2025-04-15 | Clear Gene, Inc. | Methods and compositions for the analysis of cancer biomarkers |
| EP3513280A4 (en) | 2017-11-13 | 2020-07-22 | The Multiple Myeloma Research Foundation, Inc. | INTEGRATED, MOLECULAR, OMIC, IMMUNOTHERAPY, METABOLIC, EPIGENETIC AND CLINICAL DATABASE |
| US10648025B2 (en) | 2017-12-13 | 2020-05-12 | Exact Sciences Development Company, Llc | Multiplex amplification detection assay II |
| AU2019230200A1 (en) * | 2018-03-08 | 2020-10-29 | University Of Notre Dame Du Lac | Systems and methods for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon |
| JP7199045B2 (ja) * | 2018-04-13 | 2023-01-05 | 国立大学法人大阪大学 | 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム |
| JP7444376B2 (ja) * | 2018-09-21 | 2024-03-06 | 国立大学法人 東京大学 | がんの予後判定方法 |
| JP2019032334A (ja) * | 2018-10-03 | 2019-02-28 | イムノヴィア・アクチエボラーグ | 乳癌関連の疾患状態を決定する方法およびこの方法における使用のためのアレイ |
| KR102216645B1 (ko) * | 2018-10-29 | 2021-02-17 | 사회복지법인 삼성생명공익재단 | 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도 |
| SG11202106130UA (en) * | 2018-12-08 | 2021-07-29 | Pfs Genomics Inc | Transcriptomic profiling for prognosis of breast cancer |
| WO2020226333A1 (ko) * | 2019-05-03 | 2020-11-12 | 주식회사 디시젠 | 암 예후 예측방법 및 이의 조성물 |
| CN111235270B (zh) * | 2019-08-29 | 2022-04-29 | 北京臻知医学科技有限责任公司 | 一种基于高通量测序法的肿瘤抗原表达检测引物及试剂盒 |
| US12165747B2 (en) * | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| AU2022220330A1 (en) * | 2021-02-12 | 2023-09-14 | Mammogen, Inc. | Biomarkers for the diagnosis of breast cancer |
| US20220285032A1 (en) * | 2021-03-08 | 2022-09-08 | Castle Biosciences, Inc. | Determining Prognosis and Treatment based on Clinical-Pathologic Factors and Continuous Multigene-Expression Profile Scores |
| CN117116345B (zh) * | 2023-07-24 | 2025-09-16 | 中国人民解放军军事科学院军事医学研究院 | 一种基于基因调控网络构建患者生存网络的方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7171311B2 (en) * | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
| EP1410011B1 (en) * | 2001-06-18 | 2011-03-23 | Rosetta Inpharmatics LLC | Diagnosis and prognosis of breast cancer patients |
| WO2003004989A2 (en) * | 2001-06-21 | 2003-01-16 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| ES2374311T3 (es) * | 2002-03-13 | 2012-02-15 | Genomic Health, Inc. | Obtención de perfil de expresión génica en tejidos tumorales biopsiados. |
| US20040067234A1 (en) * | 2002-07-11 | 2004-04-08 | Paz Einat | Isocitrate dehydrogenase and uses thereof |
| US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| AU2004258085B2 (en) * | 2003-07-10 | 2010-05-27 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
| JP2007527247A (ja) * | 2004-03-05 | 2007-09-27 | ロゼッタ インファーマティクス エルエルシー | 臨床的基準および情報提供性遺伝子セットの組合せを使用する乳癌患者の分類 |
| EP1797429A2 (en) * | 2004-09-30 | 2007-06-20 | Bayer HealthCare AG | Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy |
| WO2006103442A2 (en) * | 2005-04-01 | 2006-10-05 | Ncc Technology Ventures Pte. Ltd. | Materials and methods relating to breast cancer classification |
| WO2006133460A2 (en) * | 2005-06-09 | 2006-12-14 | Yale University | Methods for diagnosing and treating breast cancer based on a her/er ratio |
| US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| AU2006259583A1 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| TWI304443B (en) * | 2005-12-30 | 2008-12-21 | Nat Health Research Institutes | Alpha-enolase specific antibody and method of use |
| US7888019B2 (en) * | 2006-03-31 | 2011-02-15 | Genomic Health, Inc. | Genes involved estrogen metabolism |
| US20100234292A1 (en) * | 2007-04-16 | 2010-09-16 | Ipsogen | Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer |
| WO2008150512A2 (en) * | 2007-06-04 | 2008-12-11 | University Of Louisville Research Foundation, Inc. | Methods for identifying an increased likelihood of recurrence of breast cancer |
| WO2009095319A1 (en) * | 2008-01-28 | 2009-08-06 | Siemens Healthcare Diagnostics Gmbh | Cancer prognosis by majority voting |
| WO2009132928A2 (en) * | 2008-05-02 | 2009-11-05 | Siemens Healthcare Diagnostics Gmbh | Molecular markers for cancer prognosis |
| EP2294215B1 (en) * | 2008-05-12 | 2013-01-16 | Genomic Health, Inc. | Tests to predict responsiveness of cancer patients to chemotherapy treatment options |
| MX337650B (es) * | 2009-11-23 | 2016-03-14 | Genomic Health Inc | Metodos para predecir el desenlace clinico del cancer. |
-
2010
- 2010-11-19 MX MX2012005822A patent/MX337650B/es active IP Right Grant
- 2010-11-19 ES ES10832289T patent/ES2735993T3/es active Active
- 2010-11-19 EP EP10832289.2A patent/EP2504451B1/en active Active
- 2010-11-19 US US12/950,732 patent/US20110123990A1/en not_active Abandoned
- 2010-11-19 WO PCT/US2010/057490 patent/WO2011063274A2/en not_active Ceased
- 2010-11-19 MX MX2016003089A patent/MX363817B/es unknown
- 2010-11-19 CA CA3043089A patent/CA3043089A1/en not_active Withdrawn
- 2010-11-19 NZ NZ599194A patent/NZ599194A/en unknown
- 2010-11-19 DK DK10832289.2T patent/DK2504451T3/da active
- 2010-11-19 PL PL10832289T patent/PL2504451T3/pl unknown
- 2010-11-19 EP EP23213439.5A patent/EP4350001A3/en active Pending
- 2010-11-19 JP JP2012540103A patent/JP5964752B2/ja active Active
- 2010-11-19 AU AU2010321829A patent/AU2010321829B2/en active Active
- 2010-11-19 EP EP20177718.2A patent/EP3739060A1/en not_active Withdrawn
- 2010-11-19 CA CA2776751A patent/CA2776751C/en active Active
- 2010-11-19 HU HUE10832289 patent/HUE044374T2/hu unknown
- 2010-11-19 MX MX2019003811A patent/MX391499B/es unknown
- 2010-11-19 EP EP19175741.8A patent/EP3556867A1/en not_active Withdrawn
-
2012
- 2012-04-04 IL IL219051A patent/IL219051A/en active IP Right Grant
-
2016
- 2016-06-30 JP JP2016129697A patent/JP2016214245A/ja active Pending
- 2016-11-23 IL IL249159A patent/IL249159A0/en unknown
-
2017
- 2017-02-03 US US15/423,977 patent/US20170211154A1/en not_active Abandoned
-
2018
- 2018-01-21 IL IL257063A patent/IL257063B/en active IP Right Grant
- 2018-08-02 JP JP2018145578A patent/JP7042717B2/ja active Active
-
2019
- 2019-01-03 IL IL264072A patent/IL264072B/en active IP Right Grant
- 2019-01-09 US US16/243,207 patent/US20190241967A1/en not_active Abandoned
-
2020
- 2020-08-04 IL IL276487A patent/IL276487B/en unknown
- 2020-09-11 US US17/018,143 patent/US20210062275A1/en not_active Abandoned
- 2020-12-28 JP JP2020218527A patent/JP2021058207A/ja active Pending
-
2022
- 2022-08-02 JP JP2022123265A patent/JP2022166064A/ja active Pending
- 2022-08-16 JP JP2022129605A patent/JP2022169647A/ja active Pending
-
2023
- 2023-12-18 JP JP2023213416A patent/JP7823012B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016214245A5 (https=) | ||
| JP2018196385A5 (https=) | ||
| Das et al. | Biomarkers in cancer detection, diagnosis, and prognosis | |
| Bai et al. | Imaging genomics in cancer research: limitations and promises | |
| Banerjee et al. | A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma | |
| Huang et al. | Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer | |
| Yang et al. | Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma | |
| Kim et al. | Sixty‐five gene‐based risk score classifier predicts overall survival in hepatocellular carcinoma | |
| Cho et al. | Gene expression signature–based prognostic risk score in gastric cancer | |
| Chun et al. | Development and external validation of an extended 10-core biopsy nomogram | |
| JP2010538609A5 (https=) | ||
| JP2016174600A5 (https=) | ||
| JP2017055769A5 (https=) | ||
| NZ599194A (en) | Methods to predict clinical outcome of cancer | |
| JP2016514966A5 (https=) | ||
| JP2016521979A5 (https=) | ||
| Zou et al. | High expression of long noncoding RNA Sox2ot is associated with the aggressive progression and poor outcome of gastric cancer | |
| Leapman et al. | New genetic markers for prostate cancer | |
| Shan et al. | [Retracted] Identification of Nine M6A‐Related Long Noncoding RNAs as Prognostic Signatures Associated with Oxidative Stress in Oral Cancer Based on Data from The Cancer Genome Atlas | |
| CN109477147A (zh) | 用于皮肤癌分期和治疗的方法和材料 | |
| WO2017044694A3 (en) | Method of determining the prognosis of hepatocellular carcinomas using a multigene signature associated with metastasis | |
| Goyen | Radiogenomic imaging-linking diagnostic imaging and molecular diagnostics | |
| Li et al. | Survival nomogram for high-grade bladder cancer patients after surgery based on the SEER database and external validation cohort | |
| Yang et al. | Radiotranscriptomics identified new mRNAs and miRNA markers for distinguishing prostate cancer from benign prostatic hyperplasia | |
| Calhoun et al. | Mitigating overdiagnosis and overtreatment in breast cancer: what is the role of the pathologist? |